$ALMS News

Guggenheim Downgrades Alumis to Neutral

Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $37

Wells Fargo Maintains Overweight on Alumis, Lowers Price Target to $25

Morgan Stanley Maintains Overweight on Alumis, Lowers Price Target to $29

HC Wainwright & Co. Upgrades Alumis to Buy, Lowers Price Target to $15

Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside

Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript

Why Is Alumis Stock Falling Tuesday?

Alumis Announces Its Phase 2b LUMUS Study Of Envudeucitinib To Treat Lupus Erythematosus Failed To Meet Primary, Secondary Endpoints

HC Wainwright & Co. Reiterates Neutral on Alumis, Maintains $25 Price Target

Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate

Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates

Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies

Alumis Reports Topline Results From Ongoing ONWARD3 Long-Term Extension Study Showing 54% Of Patients Reached Complete Skin Clearance After 48 Weeks Of Continuous Envudeucitinib Treatment

HC Wainwright & Co. Reiterates Neutral on Alumis, Maintains $25 Price Target

Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon

Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements

Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model?

Chardan Capital Maintains Buy on Alumis, Raises Price Target to $40